drugset / Trial / NCT02513342
Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.
Timeline
- Start
- 2015-03
- Primary completion
- 2017-10
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 30 mg | Intravenous |